MY187357A - Pharmaceutical composition comprising bisoprolol and perindoril - Google Patents
Pharmaceutical composition comprising bisoprolol and perindorilInfo
- Publication number
- MY187357A MY187357A MYPI2017701538A MYPI2017701538A MY187357A MY 187357 A MY187357 A MY 187357A MY PI2017701538 A MYPI2017701538 A MY PI2017701538A MY PI2017701538 A MYPI2017701538 A MY PI2017701538A MY 187357 A MY187357 A MY 187357A
- Authority
- MY
- Malaysia
- Prior art keywords
- bisoprolol
- pharmaceutical composition
- perindoril
- composition
- perindopril
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Fixed pharmaceutical composition comprising a beta blocker, bisoprolol, and an angiotensin converting enzyme inhibitor, perindopril, and use of said composition in the treatment and prevention of cardiovascular diseases and more especially arterial hypertension, stable coronary artery disease or chronic heart failure. Medicaments.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1460654A FR3027803B1 (en) | 2014-11-05 | 2014-11-05 | PHARMACEUTICAL COMPOSITION COMPRISING A BETABLOQUANT AND A CONVERSION ENZYME INHIBITOR |
PCT/FR2015/052975 WO2016071631A1 (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising bisoprolol and perindoril |
Publications (1)
Publication Number | Publication Date |
---|---|
MY187357A true MY187357A (en) | 2021-09-22 |
Family
ID=52345359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2017701538A MY187357A (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising bisoprolol and perindoril |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP3215130B1 (en) |
CY (1) | CY1123322T1 (en) |
DK (1) | DK3215130T3 (en) |
EA (1) | EA032808B1 (en) |
ES (1) | ES2811904T3 (en) |
FR (1) | FR3027803B1 (en) |
GE (1) | GEP20196989B (en) |
HR (1) | HRP20201518T1 (en) |
HU (1) | HUE051947T2 (en) |
LT (1) | LT3215130T (en) |
MA (1) | MA40915B1 (en) |
MX (1) | MX2017005848A (en) |
MY (1) | MY187357A (en) |
PH (1) | PH12017500786B1 (en) |
PL (1) | PL3215130T3 (en) |
PT (1) | PT3215130T (en) |
RS (1) | RS60657B1 (en) |
RU (1) | RU2702362C2 (en) |
SG (2) | SG11201703550SA (en) |
SI (1) | SI3215130T1 (en) |
TN (1) | TN2017000170A1 (en) |
UA (1) | UA122131C2 (en) |
WO (1) | WO2016071631A1 (en) |
ZA (1) | ZA201703078B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2024004714A (en) | 2021-10-20 | 2024-05-10 | Servier Lab | Novel trimetazidine salts. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003092729A1 (en) | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
WO2007010501A2 (en) * | 2005-07-22 | 2007-01-25 | Ranbaxy Laboratories Limited | A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor |
HU230877B1 (en) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stable pharmaceutical combination |
AU2010242938A1 (en) * | 2009-04-30 | 2011-11-17 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
WO2011138772A1 (en) | 2010-05-06 | 2011-11-10 | Cal International Limited | A pharmaceutical composition comprising aspirin and bisoprolol |
-
2014
- 2014-11-05 FR FR1460654A patent/FR3027803B1/en active Active
-
2015
- 2015-11-03 MA MA40915A patent/MA40915B1/en unknown
- 2015-11-04 RS RS20200954A patent/RS60657B1/en unknown
- 2015-11-04 UA UAA201705309A patent/UA122131C2/en unknown
- 2015-11-04 PL PL15807949T patent/PL3215130T3/en unknown
- 2015-11-04 MX MX2017005848A patent/MX2017005848A/en active IP Right Grant
- 2015-11-04 PT PT158079491T patent/PT3215130T/en unknown
- 2015-11-04 EA EA201790772A patent/EA032808B1/en unknown
- 2015-11-04 MY MYPI2017701538A patent/MY187357A/en unknown
- 2015-11-04 EP EP15807949.1A patent/EP3215130B1/en not_active Revoked
- 2015-11-04 LT LTEP15807949.1T patent/LT3215130T/en unknown
- 2015-11-04 HU HUE15807949A patent/HUE051947T2/en unknown
- 2015-11-04 DK DK15807949.1T patent/DK3215130T3/en active
- 2015-11-04 SI SI201531387T patent/SI3215130T1/en unknown
- 2015-11-04 GE GEAP201514507A patent/GEP20196989B/en unknown
- 2015-11-04 ES ES15807949T patent/ES2811904T3/en active Active
- 2015-11-04 TN TN2017000170A patent/TN2017000170A1/en unknown
- 2015-11-04 SG SG11201703550SA patent/SG11201703550SA/en unknown
- 2015-11-04 WO PCT/FR2015/052975 patent/WO2016071631A1/en active Application Filing
- 2015-11-04 RU RU2017115341A patent/RU2702362C2/en active
- 2015-11-04 SG SG10201903656RA patent/SG10201903656RA/en unknown
-
2017
- 2017-04-27 PH PH12017500786A patent/PH12017500786B1/en unknown
- 2017-05-04 ZA ZA201703078A patent/ZA201703078B/en unknown
-
2020
- 2020-09-07 CY CY20201100839T patent/CY1123322T1/en unknown
- 2020-09-23 HR HRP20201518TT patent/HRP20201518T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CY1123322T1 (en) | 2021-12-31 |
HRP20201518T1 (en) | 2020-12-11 |
UA122131C2 (en) | 2020-09-25 |
ES2811904T3 (en) | 2021-03-15 |
LT3215130T (en) | 2020-08-25 |
PH12017500786A1 (en) | 2017-10-02 |
RU2017115341A (en) | 2018-11-05 |
WO2016071631A1 (en) | 2016-05-12 |
FR3027803A1 (en) | 2016-05-06 |
EA032808B1 (en) | 2019-07-31 |
SG10201903656RA (en) | 2019-05-30 |
SG11201703550SA (en) | 2017-06-29 |
MA40915B1 (en) | 2020-08-31 |
EP3215130A1 (en) | 2017-09-13 |
PL3215130T3 (en) | 2020-11-16 |
EP3215130B1 (en) | 2020-07-08 |
SI3215130T1 (en) | 2020-11-30 |
PH12017500786B1 (en) | 2017-10-02 |
PT3215130T (en) | 2020-08-26 |
MX2017005848A (en) | 2017-06-27 |
FR3027803B1 (en) | 2018-02-09 |
GEP20196989B (en) | 2019-07-10 |
EA201790772A1 (en) | 2017-09-29 |
HUE051947T2 (en) | 2021-03-29 |
DK3215130T3 (en) | 2020-09-21 |
TN2017000170A1 (en) | 2018-10-19 |
ZA201703078B (en) | 2020-11-25 |
RU2017115341A3 (en) | 2019-05-21 |
RU2702362C2 (en) | 2019-10-08 |
RS60657B1 (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007989A (en) | Compositions and methods for treating pterygium. | |
MX2020009780A (en) | Autotaxin inhibitor compounds. | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
EA201500934A1 (en) | CARDIO AND NEPHROPROTECTIVE ANTI-DIABETIC THERAPY | |
EP3261671A4 (en) | Combination therapy for treatment of coronary artery disease | |
WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
EP3843620A4 (en) | Self-calibrating, cuffless, and non-invasive blood pressure monitor | |
PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
WO2015179823A3 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
WO2014036242A3 (en) | Benzothiazole or benzoxazole compounds as sumo activators | |
UA118474C2 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
MD20180049A2 (en) | Pharmaceutical composition | |
MY187357A (en) | Pharmaceutical composition comprising bisoprolol and perindoril | |
PH12017501979A1 (en) | Pharmaceutical compound | |
WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
WO2016144704A3 (en) | Heterocyclic autotaxin inhibitor compounds | |
GB2549031A (en) | Methods and drug therapies for patency of occluded blood vessels following angioplasty | |
PH12020500295A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same | |
TN2018000344A1 (en) | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
TH1501007280A (en) | Oral formulation for the treatment of heart and circulatory diseases. (Cardiovascular Diseases) | |
MX2014015781A (en) | Use of a1d-adrenergic antagonist, bmy-7378, for the treatment of prevention and reversal of the vascular hypertrophy in the arterial hypertension. | |
TH1601003484A (en) | Isochromine derivatives as a phosphoinoxide 3-kinase inhibitor |